CCR-7 EVs
EVs bioengineered with human CCR-7 GPCR
Reference X137
CCR-7 EVs are bioengineered EVs, harbouring human CCR-7 (human C-C chemokine receptor type 7) GPCR at their surface using Ciloa’s pilot peptide technology.
CCR-7 EVs are produced in human embryonic kidney (HEK) 293T cell line and purified according to in-EV purification process, combining Tangential Flow Filtration and chromatography. Pure CCR-7 EVs are subjected to standardised quality controls showing the total protein content, the number of particles, the EV size distribution, the presence of internal EV markers and the absence of cell protein contaminants. A direct ELISA on pure CCR-7 EVs reveals the CD81 surface marker. Cellular expression of CCR-7 and its sorting with EVs, are given.
Strengths of CCR-7 EVs
o  Purity: in-EV standardised purification process combining Tangential Flow Filtration (TFF) and chromatography allows to obtain highly purified EVs.
o  Quality: CCR-7 EVs have been characterised using in-EV standardised quality controls.
o  Storage: CCR-7 EVs are in a simple buffer and are stable at +4°C for several months.
o  Native: CCR-7 GPCR expressed in its mature conformation.
o  Many applications: CCR-7 EVs can be used to study molecular interactions with ligands, specific antibodies or small molecules.
| Total protein quantity of pure EVs | 50 µg | 100 µg |
| Particle number (Nano-flow cytometry) | ≥ 1010 particles | ≥ 2 x 1010 particles |
| Particle size (Nano-flow cytometry) | Median size of 60-70 nm | |
| Source | HEK293T cells | |
| Buffer | PBS 1X – BSA 10 µg/mL | |
| Storage | Store sterile at +4°C up to 6 months | |
Schematic representation of CCR-7 EVs
Created using biorender.com
Western Blot analysis showing that CCR-7 on EVs acquired post-translational modifications such as N-glycosylation.